852 related articles for article (PubMed ID: 26976701)
21. Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis.
Hernandez L; Lanitis T; Cele C; Toro-Diaz H; Gibson A; Kuznik A
J Manag Care Spec Pharm; 2018 Jul; 24(7):608-616. PubMed ID: 29952707
[TBL] [Abstract][Full Text] [Related]
22. Open Payments Database: Anti-Vascular Endothelial Growth Factor Agent Payments to Ophthalmologists.
Singh N; Chang JS; Rachitskaya AV
Am J Ophthalmol; 2017 Jan; 173():91-97. PubMed ID: 27697472
[TBL] [Abstract][Full Text] [Related]
23. Medicare costs for neovascular age-related macular degeneration, 1994-2007.
Day S; Acquah K; Lee PP; Mruthyunjaya P; Sloan FA
Am J Ophthalmol; 2011 Dec; 152(6):1014-20. PubMed ID: 21843875
[TBL] [Abstract][Full Text] [Related]
24. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
[TBL] [Abstract][Full Text] [Related]
25. An Analysis of Medicare Reimbursement to Ophthalmologists: Years 2012 to 2013.
Han E; Baisiwala S; Jain A; Bundorf MK; Pershing S
Am J Ophthalmol; 2017 Oct; 182():133-140. PubMed ID: 28784553
[TBL] [Abstract][Full Text] [Related]
26. Treating age-related macular degeneration: comparing the use of two drugs among medicare and veterans affairs populations.
Pershing S; Pal Chee C; Asch SM; Baker LC; Boothroyd D; Wagner TH; Bundorf MK
Health Aff (Millwood); 2015 Feb; 34(2):229-38. PubMed ID: 25646102
[TBL] [Abstract][Full Text] [Related]
27. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
Day S; Acquah K; Mruthyunjaya P; Grossman DS; Lee PP; Sloan FA
Am J Ophthalmol; 2011 Aug; 152(2):266-72. PubMed ID: 21664593
[TBL] [Abstract][Full Text] [Related]
28. Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA.
Lotery AJ; Regnier S
Eye (Lond); 2015 Mar; 29(3):380-7. PubMed ID: 25572584
[TBL] [Abstract][Full Text] [Related]
29. Canadian preference and trends survey results for anti-VEGF treatment of macular edema.
Rayat JS; Grewal PS; Whelan J; Tennant MT; Choudhry N
Can J Ophthalmol; 2016 Jun; 51(3):233-7. PubMed ID: 27316276
[No Abstract] [Full Text] [Related]
30. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
31. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
[TBL] [Abstract][Full Text] [Related]
32. The Impact of International Pricing Index Models on Anti-Vascular Endothelial Growth Factor (VEGF) Drug Costs in the United States.
Choi S; Chen EM; Chen D; Sridhar J; Parikh R
Semin Ophthalmol; 2022 Jan; 37(1):23-28. PubMed ID: 33822670
[TBL] [Abstract][Full Text] [Related]
33. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.
Holekamp NM; Liu Y; Yeh WS; Chia Y; Kiss S; Almony A; Kowalski JW
Am J Ophthalmol; 2014 Apr; 157(4):825-833.e1. PubMed ID: 24388973
[TBL] [Abstract][Full Text] [Related]
34. Economic Value of Anti-Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States.
Mulligan K; Seabury SA; Dugel PU; Blim JF; Goldman DP; Humayun MS
JAMA Ophthalmol; 2020 Jan; 138(1):40-47. PubMed ID: 31725830
[TBL] [Abstract][Full Text] [Related]
35. Anti-vascular endothelial growth factors treatment of wet age-related macular degeneration: from neurophysiology to cost-effectiveness.
Vottonen P
Acta Ophthalmol; 2018 Feb; 96 Suppl A109():1-46. PubMed ID: 29468838
[No Abstract] [Full Text] [Related]
36. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT
Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983
[TBL] [Abstract][Full Text] [Related]
37. Blood Pressure Is Associated with Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Patients with Diabetes.
Shah AR; Van Horn AN; Verchinina L; Wichorek M; Su L; Markel D; Gardner TW
Ophthalmol Retina; 2019 May; 3(5):410-416. PubMed ID: 31044732
[TBL] [Abstract][Full Text] [Related]
38. Cost and Selection of Ophthalmic Anti-Vascular Endothelial Growth Factor Agents.
Li E; Greenberg PB; Voruganti I; Krzystolik MG
R I Med J (2013); 2016 May; 99(5):15-7. PubMed ID: 27128510
[TBL] [Abstract][Full Text] [Related]
39. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration.
Shaikh AH; Toussaint BW; Miller DM; Petersen MR; Foster RE; Riemann CD; Hutchins RK; Sisk RA
Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):62-6. PubMed ID: 25559511
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
Vottonen P; Kankaanpää E
Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
